105 related articles for article (PubMed ID: 11365998)
1. ABT-378: a second generation protease inhibitor.
Highleyman L
BETA; 1998 Oct; ():8, 55. PubMed ID: 11365998
[TBL] [Abstract][Full Text] [Related]
2. Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir.
Hills-Nieminen C; Hughes CA; Houston S; Shafran SD
Ann Pharmacother; 2009 Dec; 43(12):2117-20. PubMed ID: 19934385
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
van der Lee M; Verweel G; de Groot R; Burger D
Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
[TBL] [Abstract][Full Text] [Related]
4. Lopinavir/ritonavir: appraisal of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2007 Apr; 43(4):221-47. PubMed ID: 17460785
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir-Ritonavir: a new protease inhibitor.
Mangum EM; Graham KK
Pharmacotherapy; 2001 Nov; 21(11):1352-63. PubMed ID: 11714208
[TBL] [Abstract][Full Text] [Related]
6. Response to the comparison of generic ritonavir (Ritomune, Cipla) and lopinavir/ritonavir tablets (Lopimune, Cipla) and the Abbott brand (Norvir soft-gel capsules and Kaletra tablets).
Chachad S; Gogtay J; Malhotra G; Purandare S
J Pharm Sci; 2010 Feb; 99(2):572-3; author reply 574. PubMed ID: 19718766
[No Abstract] [Full Text] [Related]
7. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
van der Lugt J; Lange J; Avihingsanon A; Ananworanich J; Sealoo S; Burger D; Gorowara M; Phanuphak P; Ruxrungtham K
Antivir Ther; 2009; 14(7):1001-4. PubMed ID: 19918104
[TBL] [Abstract][Full Text] [Related]
8. Lopinavir/ritonavir (ABT-378/r).
Qazi NA; Morlese JF; Pozniak AL
Expert Opin Pharmacother; 2002 Mar; 3(3):315-27. PubMed ID: 11866671
[TBL] [Abstract][Full Text] [Related]
9. ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis.
Izzedine H; Launay-Vacher V; Legrand M; Lieberherr D; Caumes E; Deray G
AIDS; 2001 Mar; 15(5):662-4. PubMed ID: 11317012
[No Abstract] [Full Text] [Related]
10. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials.
Hill A; van der Lugt J; Sawyer W; Boffito M
AIDS; 2009 Nov; 23(17):2237-45. PubMed ID: 19809270
[TBL] [Abstract][Full Text] [Related]
11. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
[TBL] [Abstract][Full Text] [Related]
12. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.
Dingemanse J; van Giersbergen PL; Patat A; Nilsson PN
Antivir Ther; 2010; 15(2):157-63. PubMed ID: 20386070
[TBL] [Abstract][Full Text] [Related]
13. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
14. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
Sham HL; Kempf DJ; Molla A; Marsh KC; Kumar GN; Chen CM; Kati W; Stewart K; Lal R; Hsu A; Betebenner D; Korneyeva M; Vasavanonda S; McDonald E; Saldivar A; Wideburg N; Chen X; Niu P; Park C; Jayanti V; Grabowski B; Granneman GR; Sun E; Japour AJ; Leonard JM; Plattner JJ; Norbeck DW
Antimicrob Agents Chemother; 1998 Dec; 42(12):3218-24. PubMed ID: 9835517
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
[TBL] [Abstract][Full Text] [Related]
16. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model.
Garren KW; Rahim S; Marsh K; Morris JB
J Pharm Sci; 2010 Feb; 99(2):626-31. PubMed ID: 19230020
[TBL] [Abstract][Full Text] [Related]
18. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans.
Kumar GN; Jayanti VK; Johnson MK; Uchic J; Thomas S; Lee RD; Grabowski BA; Sham HL; Kempf DJ; Denissen JF; Marsh KC; Sun E; Roberts SA
Pharm Res; 2004 Sep; 21(9):1622-30. PubMed ID: 15497688
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
